Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.
Cabaletta Bio, Inc. (CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, and Artisan Bio, Inc., a precision cell therapy engineering company, today announced they have signed a research and collaboration agreement to accelerate development of next-generation CAAR T cell therapies for patients with B cell-mediated autoimmune diseases. “This collaboration agreement with Artisan provides Cabaletta Labs with the potential to integrate this advanced gene editing and engineering technology into our next-generation CAAR T products as we continue to expand and enhance our CABA platform,” said Gwendolyn Binder, Ph.D., EVP Science and Technology at Cabaletta Bio.
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]